Cylatron peginterferon alfa-2b regulatory update

Schering-Plough withdrew an MAA for Cylatron peginterferon alfa-2b as an adjuvant treatment of stage III melanoma. The company said it withdrew the application based on the view of the EMEA's CHMP tha...